New combo therapy aims to delay prostate cancer progression

NCT ID NCT05133440

First seen Feb 01, 2026 · Last updated Apr 30, 2026 · Updated 12 times

Summary

This study tested whether adding a radioactive drug called Radium-223 to standard targeted radiation (SBRT) helps men whose prostate cancer has returned in a few bone spots but hasn't yet become hormone-resistant. Twelve men participated, receiving either SBRT alone or SBRT plus Radium-223. The goal was to see if the combination could delay cancer progression longer than SBRT alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack (Limited Protocol Activities)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    Harrison, New York, 10604, United States

  • University of Colorado (Data Collection Only)

    Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.